PCSK9 inhibitors in clinical practice: novel directions and new experiences.

[1]  Diederick Grobbee,et al.  Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry , 2019, European journal of preventive cardiology.

[2]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[3]  G. Kolovou,et al.  Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). , 2018, Atherosclerosis.

[4]  C. Ballantyne,et al.  Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. , 2018, Journal of clinical lipidology.

[5]  B. Zafrir,et al.  Lipid‐lowering therapy with PCSK9‐inhibitors in the real‐world setting: Two‐year experience of a regional lipid clinic , 2018, Cardiovascular therapeutics.

[6]  R. Rosenson,et al.  Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials , 2018, Cardiovascular Drugs and Therapy.

[7]  E. Stroes,et al.  PCSK9 inhibitors in clinical practice: Delivering on the promise? , 2017, Atherosclerosis.

[8]  L. Rallidis,et al.  Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy. , 2017, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[9]  M. Hlatky,et al.  PCSK9 Inhibitors: Economics and Policy. , 2017, Journal of the American College of Cardiology.

[10]  J. Kleijnen,et al.  Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia , 2017, Journal of the American Heart Association.

[11]  Alan S. Brown,et al.  Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. , 2017, Journal of clinical lipidology.

[12]  R. Giugliano,et al.  Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial , 2017, JAMA cardiology.

[13]  E. Sijbrands,et al.  Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. , 2017, Journal of clinical lipidology.

[14]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[15]  J. Zamorano,et al.  European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk , 2016, European heart journal.

[16]  S. Humphries,et al.  Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. , 2016, The lancet. Diabetes & endocrinology.

[17]  L. Rallidis,et al.  Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. , 2016, Atherosclerosis.

[18]  C. Ballantyne,et al.  Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. , 2016, JAMA.

[19]  G. Watts,et al.  Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. , 2016, Journal of the American College of Cardiology.

[20]  G. Kolovou,et al.  Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors , 2016, HORMONES.

[21]  Dirk De Bacquer,et al.  Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. , 2015, Atherosclerosis.

[22]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[23]  U. Laufs,et al.  Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. , 2013, Journal of the American College of Cardiology.

[24]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[25]  F. Civeira,et al.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. , 2004, Atherosclerosis.